Cargando…

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants

Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as effective and safe for the treatment of acute venous thromboembolism as warfarin. Here, we rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geldhof, Vincent, Vandenbriele, Christophe, Verhamme, Peter, Vanassche, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314657/ https://www.ncbi.nlm.nih.gov/pubmed/25650285 http://dx.doi.org/10.1186/1477-9560-12-21

Ejemplares similares

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations
por: Douxfils, Jonathan, et al.
Publicado: (2015)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis
por: Zuin, Marco, et al.
Publicado: (2023)

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
por: Woodruff, Seth, et al.
Publicado: (2016)

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
por: Douxfils, Jonathan, et al.
Publicado: (2014)

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
por: Zeng, Jie, et al.
Publicado: (2019)

Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
por: Weitz, Jeffrey I., et al.
Publicado: (2020)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2021)

Case report: Application of non-VKA oral anticoagulants in patient of idiopathic hypereosinophilic syndrome with intracardiac thrombus
por: Zou, Man, et al.
Publicado: (2022)

Screening for venous thromboembolism in patients with COVID-19
por: Vandenbriele, Christophe, et al.
Publicado: (2021)

Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis
por: Zuin, Marco, et al.
Publicado: (2022)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Efficacy of Direct Oral Anticoagulant into the Care of Venous Thromboembolism Related to Kumamoto Earthquake
por: Matsukawa, Mai, et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis
por: Katel, Anjan, et al.
Publicado: (2021)

Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation
por: Tosetto, Alberto, et al.
Publicado: (2015)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)

Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism
por: Ullah, Fauzia, et al.
Publicado: (2023)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era
por: Toth, Peter P
Publicado: (2016)

Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
por: Finks, Shannon W., et al.
Publicado: (2016)

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014)

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Planquette, Benjamin, et al.
Publicado: (2019)

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Streiff, Michael B., et al.
Publicado: (2018)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants—A Retrospective Cohort Study
por: Ayalon-Dangur, Irit, et al.
Publicado: (2021)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
por: Lorenzo, Alicia, et al.
Publicado: (2022)

Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis
por: Castellucci, Lana A, et al.
Publicado: (2013)

Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2014)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
por: van den Heuvel, J. M., et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation
por: Kailas, Shilpa D, et al.
Publicado: (2016)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_l8i44f8thqjhf6q16h3pdhmtqr